Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I
https://doi.org/10.15829/1560-4071-2021-4368
Abstract
Aim. To assess the healthcare system costs for the management of patients with heart failure (HF) based on a retrospective analysis of primary medical documentation.
Material and methods. We performed the analysis of outpatient records of 1000 patients, followed up for 1 year by a general practitioner or cardiologist in ambulatory clinic in 7 Russian regions. The study included men and women over 18 years of age with an established class II-IV HF and at least one hospitalization due to acute decompensated HF within 12-month follow-up.
Results. The final analysis included 888 patients (men, 52,9%; women, 47,1%; mean age, 69 [61; 78] years). The preserved ejection fraction (EF) was detected in 47,86% of patients, mid-range — in 40,54%, reduced — in 11,6%. Only in 16% of patients, there was improved by 1 or more HF. Hypertension and coronary artery disease were predominant in etiology pattern of HF. Preserved EF was more often detected in women over 60 years of age, with HTN and obesity, as well as with HF with mid-range and reduced EF in men in the same age group. There was sufficient follow-up rate, but the extent examinations do not correspond to the recommended one. The prescription rate of renin-angiotensin-aldosterone system (RAAS) inhibitors corresponds to the recommended one, but there is a high frequency of prescribing angiotensin II receptor blockers (ARBs). The prescription rate of β-blockers and loop diuretics (mainly torasemide) increased in comparison with previous studies, while thiazide diuretics — decreased. In patients with reduced EF, the prescription rate of sacubitril/valsartan was only 14,7%, β-blockers — 83,3%, mineralocorticoid receptor antagonists (MCRA) — 72,5%. In patients with midrange EF, there was a sharp decrease in prescription rate of RAAS inhibitors, β-blockers, MCRA.
Conclusion. The practical follow-up of patients with HF differs significantly from clinical guidelines. Due to inadequate pharmacotherapy, as well as insufficient noncompliance with the recommended extent of investigations, 1-year HF therapy does not lead to a pronounced improvement in the patients' class.
About the Authors
Yu. M. LopatinRussian Federation
Volgograd.
Competing Interests:
Конфликт интересов не заявляется
S. V. Nedogoda
Russian Federation
Volgograd.
Competing Interests:
Конфликт интересов не заявляется
M. V. Arkhipov
Russian Federation
Yekaterinburg.
Competing Interests:
Конфликт интересов не заявляется
A. S. Galyavich
Russian Federation
Kazan.
Competing Interests:
Конфликт интересов не заявляется
N. A. Koziolova
Russian Federation
Perm.
Competing Interests:
Конфликт интересов не заявляется
N. G. Lozhkina
Russian Federation
Novosibirsk.
Competing Interests:
Конфликт интересов не заявляется
E. V. Reznik
Russian Federation
Moscow.
Competing Interests:
Конфликт интересов не заявляется
A. S. Salasyuk
Russian Federation
Volgograd.
Competing Interests:
Конфликт интересов не заявляется
M. Yu. Frolov
Russian Federation
Volgograd.
Competing Interests:
Конфликт интересов не заявляется
A. I. Chesnikova
Russian Federation
Rostov-on-Don.
Competing Interests:
Конфликт интересов не заявляется
E. V. Chumachek
Russian Federation
Volgograd.
Competing Interests:
Конфликт интересов не заявляется
L. A. Shpagina
Russian Federation
Novosibirsk.
Competing Interests:
Конфликт интересов не заявляется
References
1. Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;(8):7-13. (In Russ.) doi:10.15829/1560-4071-2016-8-7-13.
2. Russian Society of Cardiology (RSC) 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):4083. (In Russ.) doi:10.15829/1560-4071-2020-4083.
3. Garganeeva AA, Bauer VA, Borel KN. Reviews and lectures. Pandemic of the 21st century: chronic heart failure is a burden of modern society. Epidemiological aspects (literature review). Siberian Medical Journal. 2014;29(3):8-12. (In Russ.)
4. Mareev VYu, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russ.) doi:10.18087/cardio.2475.
5. Sitnikova MYu, Lyasnikova EA, Yurchenko AV, et al. Results of 3 years work of the Russian hospital register of chronic heart failure (RUssian hoSpital Heart Failure Registry — RUS-HFR): relationship between management and outcomes in patients with chronic heart failure. Kardiologiia. 2018;58(10S):9-19. (In Russ.) doi:10.18087/cardio.2483.
6. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. doi:10.1002/ejhf.592.
7. Fomin IV, Belenkov YuN, Mareev Vyu, et al. The prevalence of chronic heart failure in the European part of the Russian Federation — EHPOHA-HSN. Zhurnal serdechnaya nedostatochnost. 2006;7(3):112-5. (In Russ.)
8. Polyakov DS, Fomin IV, Valikulova FYu, Vaysberg AR, et al. The EPOCH-CHF epidemiological program: decompensated chronic heart failure in real-life clinical practice (EPOCH-D-CHF). Russian Heart Failure Journal. 2016;17(5):299-305. (In Russ.) doi:10.18087/rhfj.2016.5.2239.
9. Guidelines for ATC classification and DDD assignment 2020. Oslo: WHO Collaborating Centre for Drug Statistics Methodology. Norwegian Institute of Public Health. 2019. Available from: https://www.whocc.no/atc_ddd_index_and_guidelines/guidelines/
10. Gorokhova SG, Riazhenov VV, Pfaf VF. On the burden of heart failure in Russia. Lechebnoe delo. 2014;3:42-50. (In Russ.)
11. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Card Fail Rev. 2017;3(1):7-11. doi:10.15420/cfr.2016:25:2.
12. Shafie AA, Tan YP, Ng CH. Systematic review of economic burden of heart failure. Heart Fail Rev. 2018;23:131-45. doi:10.1007/s10741-017-9661-0.
13. Mozaffarian D, Benjamin EJ, Go AS, et al. American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2016 Update: A report from the American Heart Association. Circulation. 2016;133:e38-e360. doi:10.1161/CIR.0000000000000350.
14. Zohrabian A, Kapp JM, Simoes EJ. The economic case for US hospitals to revise their approach to heart failure readmission reduction. Ann Transl Med. 2018;6(15):298. doi:10.21037/atm.2018.07.30.
15. Belenkov YuN, Mareev VYu, Ageev FT, et al. The true prevalence of CHF in the European part of the Russian Federation (hospital stage). Zhurnal serdechnaya nedostatochnost. 2011;12(2):63-8. (In Russ.)
16. Cleland J. The EuroHeart Failure survey programme — a survey on the quality of care among patients with heart failure in Europe Part 1: patient characteristics and diagnosis. European Heart Journal. 2003;24(5):442-63. doi:10.1016/S0195-668X(02)00823-0.
17. Dushina AG, Lopina EA, Libis RA. Features of chronic heart failure depending on the left ventricular ejection fraction. Russian Journal of Cardiology. 2019;(2):7-11. (In Russ.) doi:10.15829/1560-4071-2019-2-7-11.
18. Reznik EV, Lazarev VA, Kalova MR, Nikitin IG. Management of patients with chronic heart failure and diabetes mellitus from the standpoint of modern practice and in real practice. Consilium Medicum. 2020;22(5):90-6. (In Russ.) doi:10.26442/20751753.2020.5.200198.
Supplementary files
Review
For citations:
Lopatin Yu.M., Nedogoda S.V., Arkhipov M.V., Galyavich A.S., Koziolova N.A., Lozhkina N.G., Reznik E.V., Salasyuk A.S., Frolov M.Yu., Chesnikova A.I., Chumachek E.V., Shpagina L.A. Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part I. Russian Journal of Cardiology. 2021;26(4):4368. https://doi.org/10.15829/1560-4071-2021-4368